Biopharmaceutical benchmarks 2014
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CHO cells are the most commonly used host cells by the recombinant biologic industry, with published reports indicating that approximately 70% of approved biotech products are manufactured using CHO.
“This result is not unexpected as CHO cells are the most commonly used host cells by the recombinant biologic-industry with published reports indicating that approximately 70% of approved biotech products are manufactured using CHO 12 .”
From Viral contamination in biologic manufacture and implications for emerging therapies (2020) · cites this paper as [12]
Since that time, the production of therapeutic proteins has largely shifted to the use of recombinant DNA technology in prokaryotic and eukaryotic cells.
“Since that time, the production of therapeutic proteins has largely shifted to the use of recombinant DNA technology in prokaryotic and eukaryotic cells 12 .”
From Viral contamination in biologic manufacture and implications for emerging therapies (2020) · cites this paper as [12]
A significant portion of approved biopharmaceutical products are recombinant proteins, and the number of them produced in mammalian expression platforms is increasing.
“A significant portion of these products are recombinant proteins, with an ongoing increase in the number of them produced in mammalian expression platforms (Walsh, 2014).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Walsh, 2014
Cited by
Sorted by citations
Alternative molecular formats and therapeutic applications for bispecific antibodies
Spiess, C., Zhai, Q., & Carter, P. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.01.003 · Cited by 607 · see citing works
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
<i>Chlamydomonas</i> as a model for biofuels and bio‐products production
Scranton, M. A., Ostrand, J. T., Fields, F. J., & Mayfield, S. P. (2015) · The Plant Journal · doi:10.1111/tpj.12780 · Cited by 267 · see citing works
Engineered CHO cells for production of diverse, homogeneous glycoproteins
Yang (2015) · Nature Biotechnology · doi:10.1038/nbt.3280 · Cited by 254 · see citing works
Pereira, S., Kildegaard, H. F., & Andersen, M. R. (2018) · Biotechnology Journal · doi:10.1002/biot.201700499 · Cited by 214 · see citing works
Viral contamination in biologic manufacture and implications for emerging therapies
Barone, P. W., Wiebe, M. E., Leung, J. C., Hussein, I. T. M., Keumurian, F. J., Bouressa, J., Brussel, A., Chen, D., Chong, M., Dehghani, H., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0507-2 · Cited by 212 · see citing works
Biotechnology of non-Saccharomyces yeasts—the ascomycetes
Johnson, E. A. (2013) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4497-y · Cited by 193 · see citing works
<scp>AB</scp> ‐Bind: Antibody binding mutational database for computational affinity predictions
Sirin, S., Apgar, J. R., Bennett, E. M., & Keating, A. E. (2016) · Protein Science · doi:10.1002/pro.2829 · Cited by 179 · see citing works
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176 · see citing works
Feichtinger, J., Hernández, I., Fischer, C., Hanscho, M., Auer, N., Hackl, M., Jadhav, V., Baumann, M., Krempl, P. M., Schmidl, C., et al. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25990 · Cited by 148 · see citing works
Immunogenicity assessment during the development of protein therapeutics
Rosenberg, A. S., & Sauna, Z. E. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12810 · Cited by 131 · see citing works
Chen, J., Ouyang, J., Chen, Q., Deng, C., Meng, F., Zhang, J., Cheng, R., Lan, Q., & Zhong, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b06879 · Cited by 124 · see citing works
A reference genome of the Chinese hamster based on a hybrid assembly strategy
Rupp, O., MacDonald, M. L., Li, S., Dhiman, H., Polson, S., Griep, S., Heffner, K., Hernandez, I., Brinkrolf, K., Jadhav, V., et al. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26722 · Cited by 107 · see citing works
Muneeruddin, K., Nazzaro, M., & Kaltashov, I. A. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b02982 · Cited by 98 · see citing works
Gao, Y., Ray, S., Dai, S., Ivanov, A. R., Abu‐Absi, N. R., Lewis, A. M., Huang, Z., Xing, Z., Borys, M. C., Li, Z. J., et al. (2016) · Biotechnology Journal · doi:10.1002/biot.201600030 · Cited by 76 · see citing works
Green biologics: the algal chloroplast as a platform for making biopharmaceuticals
Taunt, H. N., Stoffels, L., & Purton, S. (2018) · Bioengineered · doi:10.1080/21655979.2017.1377867 · Cited by 81 · see citing works
Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75 · see citing works
Enzyme capacity-based genome scale modelling of CHO cells
Yeo, H. C., Hong, J., Lakshmanan, M., & Lee, D.-Y. (2020) · Metabolic Engineering · doi:10.1016/j.ymben.2020.04.005 · Cited by 75 · see citing works
Glycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70 · see citing works
Elevated pCO<sub>2</sub> affects the lactate metabolic shift in CHO cell culture processes
Brunner, M., Doppler, P., Klein, T., Herwig, C., & Fricke, J. (2018) · Engineering in Life Sciences · doi:10.1002/elsc.201700131 · Cited by 63 · see citing works
Rafferty, C., Johnson, K., O'Mahony, J., Burgoyne, B., Rea, R., & Balss, K. M. (2020) · Biotechnology Progress · doi:10.1002/btpr.2977 · Cited by 63 · see citing works
Amann, T., Schmieder, V., Faustrup Kildegaard, H., Borth, N., & Andersen, M. R. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27101 · Cited by 46 · see citing works
High level in vivo mucin-type glycosylation in Escherichia coli
Mueller, P., Gauttam, R., Raab, N., Handrick, R., Wahl, C., Leptihn, S., Zorn, M., Kussmaul, M., Scheffold, M., Eikmanns, B., et al. (2018) · Microbial Cell Factories · doi:10.1186/s12934-018-1013-9 · Cited by 22 · see citing works
Guerrero Montero, I., Richards, K. L., Jawara, C., Browning, D. F., Peswani, A. R., Labrit, M., Allen, M., Aubry, C., Davé, E., Humphreys, D. P., et al. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27147 · Cited by 22 · see citing works
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156 · see citing works
- Authors
- Walsh, G.
- Affiliations
- University of Limerick (IE)
- Corresponding author
- Walsh, Gary
- ORCID
- Walsh, Gary
- Venue
- Nature Biotechnology
- Published
- 2014-10
- Volume
- 32
- Issue
- 10
- Pages
- 992-1000
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2917973694
- Cited by
- 1,008
- References
- 0
- Citations by year
- 2026: 14 · 2025: 22 · 2024: 19 · 2023: 28 · 2022: 30 · 2021: 66 · 2020: 88 · 2019: 108 · 2018: 147 · 2017: 173 · 2016: 136 · 2015: 95 · 2014: 41 · 2013: 33 · 2012: 7
- FWCI
- 62.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- biopharmaceutical market, monoclonal antibodies, biobetters, biosimilars, biosimilar approval, biologic drugs, drug market growth
- MeSH terms
- Animals, Antibodies, Monoclonal, Biopharmaceutics, Biotechnology, Drug Industry, Europe, Humans, United States, Genetic Therapy, Drug Approval, Biomedical Research, Mice, Biosimilar Pharmaceuticals
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
